DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Holiday Inn London Kensington Forum

2016 年 11 月 14 日 8:00 上午 - 2016 年 11 月 18 日 1:30 下午

97 Cromwell Road, London, SW7 4DN, United Kingdom

Joint MHRA/DIA Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

The 5 days of training include a comprehensive overview of the core processes and systems in place and the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

TOPIC 1: DEFINITIONS AND METHODS IN PHARMACOVIGILANCE

Session Chair(s)

Gaby L. Danan, MD, PHD

Gaby L. Danan, MD, PHD

Pharmacovigilance Expert

GLD, France

Phil  Tregunno

Phil Tregunno

Deputy Director - Patient Safety Monitoring

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Topic 1 will provide a concise overview of the objectives and the scope of Pharmacovigilance. The development of key definitions based on Community legislation and consensus, such as the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and the CIOMS Working Groups will be summarised. Practical examples and exercises will be used to illustrate the key definitions in Pharmacovigilance and the methods used in Pharmacovigilance in order to detect signals. The Risk Management process will be described, including the main components of the Risk Management Plan.

Speaker(s)

Gaby L. Danan, MD, PHD

Basic Definitions and Tools in Pharmacovigilance

Gaby L. Danan, MD, PHD

GLD, France

Pharmacovigilance Expert

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。